Prosecution Insights
Prosecution Insights
106 pending office actions • 40 art units • 88 examiners • 0 of 106 (0%) have an AI response strategy ready • 166 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 101 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 101 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (3%) |
| §103 only | 54 (51%) |
| §102 only | 7 (7%) |
| §112 only | 16 (15%) |
| No statute on record | 26 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWARD, ZACHARY C | 3 | 63.9% | +38.2% |
| MCKNIGHT, CIARA A | 3 | 61.8% | +34.7% |
| XU, XIAOYUN | 3 | 59.6% | +32.3% |
| KAPUSHOC, STEPHEN THOMAS | 3 | 46.6% | +52.8% |
| WILSON, MICHAEL C | 3 | 41.7% | +17.6% |
| HOPKINS, SAMANTHA LAKE | 2 | 57.9% | +61.5% |
| CANDELARIA, JULIANA IRENE | 2 | — | — |
| O'BRIEN, LEA S | 2 | 50.0% | +8.3% |
| ALLEN, MARIANNE P | 2 | 59.8% | +18.5% |
| XIE, XIAOZHEN | 2 | 55.9% | +65.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18340917 | NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE | CANDELARIA, JULIANA IRENE | 12d |
| 17602562 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | O'BRIEN, LEA S | 26d |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | AEDER, SEAN E | 42d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18045588 | ANTIBODIES TO HUMAN GDF8 | XIE, XIAOZHEN | 146d overdue |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 127d overdue |
| 18101310 | Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies | XIE, XIAOZHEN | 120d overdue |
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | WILSON, MICHAEL C | 100d overdue |
| 16991283 | GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | WILSON, MICHAEL C | 79d overdue |
| 18389403 | METHODS FOR ASSAYING ENZYME ACTIVITY | MCKNIGHT, CIARA A | 73d overdue |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 73d overdue |
| 18257793 | NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 52d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 10 |
| 1641 | 6 |
| 1647 | 6 |
| 1637 | 6 |
| 1643 | 6 |
| 1675 | 5 |
| 1683 | 5 |
| 3783 | 4 |
| 1638 | 4 |
| 1656 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §103 | Final Rejection | 43d | Pending | Sep 18, 2025 |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 1641 | §112 | Final Rejection | 8d | Pending | Jun 25, 2025 |
| 18680910 | ANTI-NPR1 ANTIBODIES AND USES THEREOF | HOWARD, ZACHARY C | 1674 | §112 | Final Rejection | 70d | Pending | May 31, 2024 |
| 18584551 | ANTI-ACVR1 ANTIBODIES AND USES THEREOF | DEBERRY, REGINA M | 1647 | §112 | Non-Final OA | 27d | Pending | Feb 22, 2024 |
| 18429887 | Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies | KAUFMAN, CLAIRE M | 1674 | Other | Final Rejection | 3d overdue | Pending | Feb 01, 2024 |
| 18420090 | SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING | DING, XIAOMAO | 2676 | §103 | Non-Final OA | 1d overdue | Pending | Jan 23, 2024 |
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | WEN, SHARON X | 1641 | Other | Non-Final OA | 30d | Pending | Jan 08, 2024 |
| 18540970 | METHODS AND SYSTEMS FOR ASSESSING CHROMATOGRAPHIC COLUMN INTEGRITY | DRODGE, JOSEPH W | 1773 | §103 | Non-Final OA | 2d overdue | Pending | Dec 15, 2023 |
| 18520007 | CAS-READY MOUSE EMBRYONIC STEM CELLS AND MICE AND USES THEREOF | QIAN, CELINE X | 1637 | §103 | Non-Final OA | 84d overdue | Pending | Nov 27, 2023 |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | KIM, TAEYOON | 1631 | Other | Non-Final OA | 35d | Pending | Nov 20, 2023 |
| 18389403 | METHODS FOR ASSAYING ENZYME ACTIVITY | MCKNIGHT, CIARA A | 1656 | §103 | Non-Final OA | 73d overdue | Pending | Nov 14, 2023 |
| 18499538 | METHODS, DEVICES, AND SYSTEMS FOR SPATIAL TRANSCRIPTOME SLIDE ALIGNMENT | FITZPATRICK, ATIBA O | 2677 | §112 | Non-Final OA | 41d | Pending | Nov 01, 2023 |
| 18485592 | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | WHITEMAN, BRIAN A | 1636 | Other | Non-Final OA | 16d | Pending | Oct 12, 2023 |
| 18482448 | ANTI-PTCRA ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HUYNH, PHUONG N | 1641 | §103 | Non-Final OA | 112d overdue | Pending | Oct 06, 2023 |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | TATGE, LEXUS MARC | 1637 | §112 | Non-Final OA | 22d | Pending | Sep 11, 2023 |
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | TAYLOR, LIA ELAN | 1641 | §103 | Non-Final OA | 8d | Pending | Sep 06, 2023 |
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | PUTTLITZ, KARL J | 1646 | §103 | Non-Final OA | 46d overdue | Pending | Aug 23, 2023 |
| 18237239 | COMMON LIGHT CHAIN MOUSE | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Non-Final OA | 60d overdue | Pending | Aug 23, 2023 |
| 18547192 | METHODS OF TREATING LUNG CANCER BY ADMINISTERING A PD-1 INHIBITOR | HOPKINS, SAMANTHA LAKE | 1641 | §102 | Non-Final OA | 61d | Pending | Aug 21, 2023 |
| 18547150 | METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY | TOTH, KAREN E | 3791 | §103 | Non-Final OA | 83d | Pending | Aug 18, 2023 |
| 18452452 | INTERFERON RECEPTOR AGONISTS AND USES THEREOF | JOHNSON, TIRONE DEREK | 1675 | §103 | Non-Final OA | 34d | Pending | Aug 18, 2023 |
| 18361367 | ANTI-TFR:PAYLOAD FUSIONS AND METHODS OF USE THEREOF | HAMA, JOANNE | 1647 | Other | Non-Final OA | 53d | Pending | Jul 28, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | SCHWECHTER, BRANDON ROSS | 1674 | §102 | Non-Final OA | 34d | Pending | Jul 19, 2023 |
| 18349012 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HECK, BRYAN WILLIAM | 1643 | Other | Non-Final OA | 28d overdue | Pending | Jul 07, 2023 |
| 18345975 | BOTULINUM NEUROTOXIN-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | LIEB, JEANETTE M | 1654 | Other | Final Rejection | 3d overdue | Pending | Jun 30, 2023 |
| 18340917 | NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE | CANDELARIA, JULIANA IRENE | 1634 | §101 | Non-Final OA | 12d | Pending | Jun 26, 2023 |
| 18336644 | FAST PROTEIN SEQUENCING | CHEU, CHANGHWA J | 1678 | Other | Non-Final OA | 28d | Pending | Jun 16, 2023 |
| 18336148 | SYSTEMS AND METHODS FOR DRUG DELIVERY TO OCULAR TISSUE | MEDWAY, SCOTT J | 3783 | §103 | Non-Final OA | 25d overdue | Pending | Jun 16, 2023 |
| 18257793 | NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | Other | Non-Final OA | 52d overdue | Pending | Jun 15, 2023 |
| 18208394 | METHODS FOR CHARACTERIZING HOST-CELL PROTEINS | FAN, LYNN Y | 1759 | §103 | Non-Final OA | 6d | Pending | Jun 12, 2023 |
| 18204801 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 1797 | Other | Non-Final OA | 28d | Pending | Jun 01, 2023 |
| 18319245 | MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND CD38 AND 4-1BB, AND USES THEREOF | SWARTWOUT, BRIANNA KENDALL | 1644 | Other | Non-Final OA | 10d overdue | Pending | May 17, 2023 |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 52d overdue | Pending | May 15, 2023 |
| 18310921 | METHODS FOR REDUCING LIPASE ACTIVITY | MCKNIGHT, CIARA A | 1656 | Other | Non-Final OA | 54d | Pending | May 02, 2023 |
| 18142196 | Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations | REN, HONG | 1647 | Other | Non-Final OA | 8d overdue | Pending | May 02, 2023 |
| 18307309 | METHODS FOR SELECTING PATIENTS FOR TREATMENT WITH AN NGF ANTAGONIST | O'BRIEN, LEA S | 1646 | §103 | Non-Final OA | 9d | Pending | Apr 26, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 1674 | §103 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §103 | Non-Final OA | 62d | Pending | Apr 03, 2023 |
| 18187564 | PRECISION DOSE DELIVERY DEVICE PLUNGER ROD INSERTION GAUGE AND METHODS THEREFOR | NGUYEN, ANDREW H | 3741 | §103 | Non-Final OA | 2d overdue | Pending | Mar 21, 2023 |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | 27d | Pending | Mar 11, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | NATARAJAN, MEERA | 1643 | §103 | Final Rejection | 4d overdue | Pending | Mar 02, 2023 |
| 18115285 | BIOREACTOR FOR ANTIBODY PRODUCTION | CANDELARIA, JULIANA IRENE | 1634 | Other | Non-Final OA | 21d | Pending | Feb 28, 2023 |
| 18175914 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | MCKNIGHT, CIARA A | 1656 | §103 | Non-Final OA | 83d | Pending | Feb 28, 2023 |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | AEDER, SEAN E | 1642 | §101 | Final Rejection | 42d | Pending | Feb 21, 2023 |
| 18167517 | COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTS | JOHNSON, ALLISON MARIE | 1638 | §103 | Non-Final OA | 52d overdue | Pending | Feb 10, 2023 |
| 18164171 | MEDICAL DEVICE PACKAGING AND RELATED METHODS | REYNOLDS, STEVEN ALAN | 3735 | §103 | Non-Final OA | 5d overdue | Pending | Feb 03, 2023 |
| 18101310 | Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies | XIE, XIAOZHEN | 1674 | Other | Non-Final OA | 120d overdue | Pending | Jan 25, 2023 |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | CASH, KAILEY ELIZABETH | 1683 | Other | Non-Final OA | 32d overdue | Pending | Jan 20, 2023 |
| 18155324 | DEVICES AND METHODS FOR A VIAL ADAPTER ASSEMBLY | ZIMBOUSKI, ARIANA | 3781 | §103 | Non-Final OA | 4d overdue | Pending | Jan 17, 2023 |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | CANELLA, KAREN A | 1643 | §103 | Non-Final OA | 20d | Pending | Jan 10, 2023 |
| 18094176 | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies | DRISCOLL, MAUREEN VARINA | 1644 | §112 | Non-Final OA | 27d | Pending | Jan 06, 2023 |
| 18067085 | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | PAK, MICHAEL D | 1674 | Other | Non-Final OA | 21d | Pending | Dec 16, 2022 |
| 18077139 | Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof | ALLEN, MARIANNE P | 1647 | Other | Non-Final OA | 23d overdue | Pending | Dec 07, 2022 |
| 18059315 | ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF | MCCOLLUM, ANDREA K | 1674 | Other | Non-Final OA | 188d overdue | Pending | Nov 28, 2022 |
| 18055895 | AUTO-INJECTOR AND RELATED METHODS OF USE | GONZALEZ, LEI NMN | 3783 | §102 | Final Rejection | 39d | Pending | Nov 16, 2022 |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 1683 | §103 | Non-Final OA | 73d overdue | Pending | Oct 31, 2022 |
| 17973638 | SYSTEMS AND METHODS FOR GENERATING LABORATORY WATER AND DISTRIBUTING LABORATORY WATER AT DIFFERENT TEMPERATURES | GURTOWSKI, RICHARD C | 1773 | §103 | Final Rejection | 6d | Pending | Oct 26, 2022 |
| 17920069 | NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE | DHAR, MATASHA | 1632 | §103 | Final Rejection | 46d overdue | Pending | Oct 20, 2022 |
| 18045588 | ANTIBODIES TO HUMAN GDF8 | XIE, XIAOZHEN | 1674 | Other | Final Rejection | 146d overdue | Pending | Oct 11, 2022 |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | ANGELL, JON E | 1637 | §112 | Non-Final OA | 13d | Pending | Sep 29, 2022 |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Non-Final OA | 4d overdue | Pending | Sep 28, 2022 |
| 17951801 | AUTO-INJECTOR WITH ANTI-ROLL FEATURES | SCHMIDT, EMILY LOUISE | 3783 | §103 | Non-Final OA | 3d overdue | Pending | Sep 23, 2022 |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | KENYON, JOHN S | 1625 | §102 | Non-Final OA | 49d overdue | Pending | Sep 22, 2022 |
| 17948496 | METHODS FOR CHARACTERIZING HOST-CELL PROTEINS | BERKELEY, EMILY R | 1796 | §103 | Non-Final OA | 32d overdue | Pending | Sep 20, 2022 |
| 17943776 | NMASS SPECTROMETRY-BASED STRATEGY FOR CHARACTERIZING HIGH MOLECULAR WEIGHT SPECIES OF A BIOLOGIC | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §103 | Non-Final OA | — | Pending | Sep 13, 2022 |
| 17930180 | HSD17B13 VARIANTS AND USES THEREOF | CHONG, KIMBERLY | 1636 | Other | Final Rejection | 30d | Pending | Sep 07, 2022 |
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17821665 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | Other | Non-Final OA | 22d overdue | Pending | Aug 23, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17885805 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 1653 | §103 | Non-Final OA | 13d | Pending | Aug 11, 2022 |
| 17872225 | METHODS FOR TREATING CHRONIC SPONTANEOUS URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 30d | Pending | Jul 25, 2022 |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 55d | Pending | Jul 21, 2022 |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | ZOU, NIANXIANG | 1671 | §103 | Non-Final OA | 20d | Pending | Jul 11, 2022 |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | 19d overdue | Pending | Jun 30, 2022 |
| 17855053 | Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112 | Non-Final OA | 28d overdue | Pending | Jun 30, 2022 |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | KAPUSHOC, STEPHEN THOMAS | 1683 | §112 | Non-Final OA | 12d | Pending | Jun 30, 2022 |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | KAPUSHOC, STEPHEN THOMAS | 1683 | §102 | Non-Final OA | 15d | Pending | Jun 30, 2022 |
| 17851845 | NMR METHODS FOR ANTIBODY HIGHER ORDER STRUCTURE COMPARABILITY | BERKELEY, EMILY R | 1796 | §103 | Final Rejection | — | Pending | Jun 28, 2022 |
| 17657254 | METHODS AND SYSTEMS FOR STERILIZATION | LEE, AHAM NMN | 1758 | §103 | Non-Final OA | 49d overdue | Pending | Mar 30, 2022 |
| 17687051 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | 18d overdue | Pending | Mar 04, 2022 |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 31d overdue | Pending | Mar 02, 2022 |
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | WILSON, MICHAEL C | 1638 | §112 | Non-Final OA | 100d overdue | Pending | Feb 21, 2022 |
| 17565104 | AUTO-INJECTOR AND RELATED METHODS OF USE | ZAMORY, JUSTIN L | 3783 | §103 | Non-Final OA | 22d | Pending | Dec 29, 2021 |
| 17616295 | NON-HUMAN ANIMALS HAVING A LIMITED LAMBDA LIGHT CHAIN REPERTOIRE EXPRESSED FROM THE KAPPA LOCUS AND USES THEREOF | SINGH, ANOOP KUMAR | 1632 | §103 | Final Rejection | 17d overdue | Pending | Dec 03, 2021 |
| 17611073 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | WU, JULIE ZHEN QIN | 1643 | §103 | Non-Final OA | 3d overdue | Pending | Nov 12, 2021 |
| 17525336 | Synaptojanin 2 (SYNJ2) Variants And Uses Thereof | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | — | Pending | Nov 12, 2021 |
| 17602562 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF | O'BRIEN, LEA S | 1646 | §101 | Final Rejection | 26d | Pending | Oct 08, 2021 |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 1631 | §103 | Non-Final OA | 6d | Pending | Aug 25, 2021 |
| 17443702 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | HUDSON, AMY ROSE | 1636 | Other | Non-Final OA | 22d | Pending | Jul 27, 2021 |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | CANELLA, KAREN A | 1643 | §102 | Non-Final OA | 8d | Pending | Jun 23, 2021 |
| 17236998 | METHODS AND SYSTEMS FOR ANALYSIS OF RECEPTOR INTERACTION | SABOUR, GHAZAL | 1686 | §103 | Non-Final OA | 4d overdue | Pending | Apr 21, 2021 |
| 17204636 | METHODS AND SYSTEMS FOR DETERMINING RESPONDERS TO TREATMENT | AUGER, NOAH ANDREW | 1687 | §103 | Non-Final OA | 22d | Pending | Mar 17, 2021 |
| 17204253 | NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN | NGUYEN, NAM P | 1678 | §102 | Non-Final OA | 26d | Pending | Mar 17, 2021 |
| 17194013 | Fascin-2 (FSCN2) Variants And Uses Thereof | WANG, CHANG YU | 1675 | §112 | Non-Final OA | 43d overdue | Pending | Mar 05, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17143890 | Use of Amino Acids to Enhance Signal in Mass Spectral Analyses | HUANG, MICKEY NMN | 1758 | Other | Final Rejection | 8d | Pending | Jan 07, 2021 |
| 17095562 | METHODS AND SYSTEMS FOR IDENTIFYING, CLASSIFYING, AND/OR RANKING GENETIC SEQUENCES | HAYES, JONATHAN EDWARD | 1685 | §103 | Final Rejection | 34d | Pending | Nov 11, 2020 |
| 17091484 | Accurate And Robust Information-Deconvolution From Bulk Tissue Transcriptomes | STRIEGEL, THEODORE CHARLES | 1685 | §103 | Final Rejection | 3d overdue | Pending | Nov 06, 2020 |
| 17078137 | Systems and Methods for Auto-Inoculation in Seed Train and Production Processes | BAILEY, STEVEN WILLIAM | 1687 | §103 | Non-Final OA | — | Pending | Oct 23, 2020 |
| 17062375 | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells | YOUNG, BRIAN ELLIS | 1684 | §103 | Final Rejection | 30d | Pending | Oct 02, 2020 |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | 4d overdue | Pending | Sep 24, 2020 |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | 53d | Pending | Aug 14, 2020 |
| 16991283 | GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | WILSON, MICHAEL C | 1638 | §103 | Final Rejection | 79d overdue | Pending | Aug 12, 2020 |
| 16817458 | CROSS-LINKED EPITOPES AND METHODS OF USE THEREOF | GROSS, CHRISTOPHER M | 1684 | §112 | Final Rejection | 44d overdue | Pending | Mar 12, 2020 |
| 16042099 | Stabilized Antibody Compositions and Methods of Producing Same | SCHULTZHAUS, JANNA NICOLE | 1685 | §103 | Final Rejection | 31d overdue | Pending | Jul 23, 2018 |
| 15766586 | STABLE PROTEIN COMPOSITIONS | SAEED, ALI S | 1616 | §103 | Non-Final OA | 83d | Pending | Apr 06, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial